This page maps the public-disclosable layer of the broader MZN IP and capability portfolio. It separates Phase 1 product-execution context from the eligible Phase 2 solo-formed assets, explains how assets of this class may be reviewed, and presents approximate analytical value ranges as examples for independent diligence — not final valuation, asking prices, or certified appraisal.
The figures shown for selected assets are market-context review scenarios, not final valuation, not certified appraisal, not transaction prices, not fundraising targets, and not asking prices. These assets are difficult to value in a normal market because most comparable capabilities are not sold openly, are retained internally as strategic IP, or exist only inside specialized organizations. There is usually no simple public price sheet for assets of this class.
For that reason, the figures are presented as approximate market-context scenarios for reviewers to test against multiple criteria: replacement cost, time-to-market advantage, scarcity, strategic relevance, reconstruction difficulty, IP potential, risk reduction, buyer-to-value logic, and the cost of not having the capability. They are intended to help evaluators understand possible order-of-magnitude questions. The final value, if any, must be determined by qualified reviewers after technical, legal/IP, commercial, provenance, and market diligence.
The purpose of this document is to demonstrate the level and class of intellectual property, architecture, and capability that MZN has mapped for review, while keeping the One-Person Unicorn threshold calculation phase-safe. Phase 1 assets are included only as context and execution evidence; the One-Person Unicorn question should be tested against eligible Phase 2 solo-formed assets. Final valuation, legal/IP review, technical audit, partner review, and commercialization belong to Phase 3.
The work behind this portfolio spans three distinct phases. Each is honest about what it was: a team-built foundation, a bounded solo formation window, and a post-formation institutional stage. Distinguishing them is essential — the solo claim applies to the middle phase only, not retroactively to the prior team work and not forward to the institutional stage now beginning.
A portfolio like this should not be valued by checking a simple public price sheet. Many comparable capabilities, where they exist, appear to be retained internally as strategic IP rather than sold as turnkey products. The framework below is an analytical path for reviewers to test whether any provisional value range is defensible for assets of this kind. Each asset is later presented with this same set of questions applied directly to it.
For each asset, apply the six questions below in order. The questions are designed to be tested independently of any claims made by MZN. The reader can test each step against publicly available information about the relevant industry, published research, documented build costs of similar work, and the observable behavior of organizations that may hold comparable internal capability. A disciplined evaluator should be free to accept, adjust, narrow, or reject any number suggested by MZN.
When the six questions above are applied to a given asset, the components — build-cost, time-to-market premium, risk reduction, strategic premium — create an approximate review scenario that is the analytical prompt of the framework, not a final claim made independently of diligence. For each asset in the catalog below, that analytical output is shown alongside the prompts that produced it.
Three assets in this portfolio are presented without a value indication at all, because the framework above cannot be honestly applied to them at this stage. For BioCode, the foundational theoretical layer, the framework cannot be applied because the complete framework has never been presented in public — any value figure would be based on partial information and would mislead in either direction. For HDTP, only the high-level architectural shell is publicly visible — the operational and IP-sensitive details that determine market value are reserved. For ISBP within the security portfolio, only the problem identification has been disclosed — the actual solutions, where the value sits, remain undisclosed. For these three, the document acknowledges what is visible and explains why valuation is reserved.
One additional discipline runs through the entire catalog: every approximate range shown represents only the public-disclosable layer of the asset. The deeper operational layers — implementation detail, complete patent claim sets, executable specifications — are reserved for controlled review. The scenarios shown should therefore not be read as a floor or a ceiling; they are review prompts until qualified diligence assigns its own view.
The evaluation framework depends on reasonable estimates of build costs, team compositions, and timelines in adjacent categories. The benchmarks below are publicly verifiable reference points that calibrate the analysis. They are not claims about MZN — they are baselines anyone can confirm.
For each asset, the same structure applies: a precise description of what the asset is, the six evaluation prompts with each prompt answered for that specific asset, and the value band that disciplined analysis yields. Assets where the framework cannot yet be honestly applied are shown with the reasoning for why valuation is reserved.
Each question below can be answered by examining publicly available information about frontier-grade AI organizations and the visible market.
The 21-slot anatomy below maps the structural requirements of a frontier-grade AI organization. For each slot, the current MZN level is marked Strong, Partial, or Gap, based on the public-disclosable evidence. This is a founder-prepared public-layer capability map designed to guide independent review — not an external audit and not an inflated claim.
MZN is Strong on the foundational architectural layers (model architecture, training, compute security, tokenizer, evaluation core, security operations, privacy governance). Partial on the alignment layers (where multi-team coordination would normally accelerate progress) and on serving infrastructure (where production rollout is deferred to Phase 3). One remaining Gap is acknowledged at D4 (customer fine-tuning). E4 is treated as Partial / Phase 3-dependent because methodology and evaluation architecture exist, while institutional research operations remain outside the solo Phase 2 scope.
The summary below organizes the public-layer scenario ranges and reserved-valuation positions. It intentionally does not publish a final aggregate portfolio valuation. A reviewer may use the figures as market-context prompts, but the defensible value, if any, should be determined independently after staged diligence.
No aggregate number on this page should be read as a final valuation, fundraising target, asking price, investment term, or partnership condition. The broader map includes A7/Mazzaneh as Phase 1 product-execution context. The One-Person Unicorn threshold test should consider only eligible Phase 2 assets and should exclude A7. BioCode, HDTP, and the ISBP solution layer are not publicly priced. A disciplined reviewer should determine any aggregate value independently after technical, legal/IP, commercial, provenance, and market diligence.
Across the portfolio, a documented pattern is observable: ideas that appear early in the MZN portfolio — with cryptographic anchoring and blockchain timestamps establishing priority dates — have subsequently appeared in frontier-research directions at multiple major AI laboratories, in some cases with material similarity to the original architectures.
The pattern is presented here as a directional review signal, not as a legal priority claim, copying claim, appropriation claim, or proof of external/platform signal. Independent convergence may suggest that MZN was operating in real frontier-relevant problem spaces, but the significance of any overlap must be tested through timestamp review, specific comparison, and independent expert judgment.
The specific overlap documentation is available at the asset-detail level under controlled review. The pattern is mentioned here at the directional level only. Cryptographic records may help establish document existence and sequence; they do not by themselves prove novelty, authorship, enforceability, market value, or legal priority.
None of the signals below were purchased, and none involved a PR firm, an agency, or a paid placement. Each represents an institutional decision made by an external organization, applying its own criteria, on the basis of artifacts submitted personally.
The recognition pattern is meaningful as a reason-to-review signal, not as proof of value, proof of One-Person Unicorn status, endorsement, certification, or permanent ranking. It is notable precisely because of how it was generated: by one person, under documented constraints, on the basis of a fraction of the total portfolio (typically two or three modules out of twenty-two presented externally), without PR infrastructure, without institutional channel access, without a Silicon Valley network. The pattern is cited as a visibility signal that should be checked by date, category, and source.
Crunchbase note: rankings are time-sensitive platform signals. MZN cites a Top 5 position across all categories in May 2026 and a #1 Machine Learning position from May 2026 to the current cited snapshot. These are reasons to investigate, not proof, endorsement, valuation, certification, or permanent status.
The portfolio is built around a layered disclosure model. This document is the public layer — and even within the public layer, the priced assets show only their public-disclosable depth. The deeper layers exist and are referenced; they are not visible here.
Document: MZN-IP-PORTFOLIO-FINAL-2026 · May 2026
Verification chain: SHA-256 hashing across priority artifacts, with timestamp records and cross-reference manifests available for staged review. Hashes and timestamps help establish document existence, sequence, and preservation; they do not by themselves prove novelty, authorship, enforceability, technical validity, or valuation.
Key reference hashes:
BioCode v1.0 → 50615aea…068505df
Multi-Brain Architecture → 46d9428b…e4f2f937
UIOP Extended → c7698b0c…55884d8f
Output-Centered Safety → a4c5bc69…4c83eb4fa
Contact: partnership@mzncompany.com · mazzaneh.company@gmail.com · Phase 3 Partner Path
I, Mohammad Rahimi, declare that I am the sole creator of the Phase 2 intellectual property described in this portfolio. The solo build phase was carried out using standard AI chat subscriptions, without a team, without collaborators, without API access, without agent frameworks, without automation stacks, and without external code-writing workflows.
Phase 1 outputs were team-built and are explicitly excluded from the one-person claim. Phase 3 is now beginning and is explicitly outside the one-person formation claim. The 21-slot capability anatomy in this document represents an honest signal of where the portfolio is Strong, Partial, and Gap — not inflated, not reframed, not optimized for evaluator sympathy.
The figures in this document are founder-prepared, market-context review scenarios applied to the public-disclosable layer of selected assets using the framework introduced in the Methodology section. They are not asking prices, not transaction targets, not commitments, not certified valuation, and not third-party appraisal. They are designed to help qualified evaluators test, adjust, narrow, or reject possible orders of magnitude through independent Phase 3 diligence.
Mohammad Rahimi · Founder, MZN Company · May 2026